论文部分内容阅读
目的观察中心静脉导管胸腔留置引流联合顺铂、重组人白细胞介素-2(rhIL-2)治疗恶性胸腔积液的临床效果。方法采用随机抽样方法,将118例经病理学或细胞学证实的恶性胸腔积液患者,分为A组和B组。A组(58例)为中心静脉导管留置引流联合顺铂、rhIL-2胸腔内注药组;B组(60例)为常规抽胸水治疗组。胸腔内注药反复3个周期,比较两组的疗效、不良反应。结果A组有效率84.5%,B组有效率57.4%,两组差异有统计学意义(P<0.01)。结论中心静脉导管引流联合顺铂、rhIL-2胸腔内注药是治疗恶性胸水安全、有效、方便的措施,值得临床应用。
Objective To observe the clinical effect of central venous catheter indwelling thoracic drainage combined with cisplatin and recombinant human interleukin-2 (rhIL-2) in the treatment of malignant pleural effusion. Methods A total of 118 patients with malignant pleural effusion confirmed by pathology or cytology were divided into A group and B group by random sampling method. Group A (58 cases) was catheterized central venous catheter combined with cisplatin, rhIL-2 intrathoracic injection group; B group (60 cases) were treated with conventional aspiration of pleural effusion. Intrathoracic injection repeated three cycles, the efficacy of the two groups, adverse reactions. Results The effective rate of group A was 84.5%, and that of group B was 57.4%. There was significant difference between the two groups (P <0.01). Conclusion Central venous catheter drainage combined with cisplatin, rhIL-2 intrathoracic injection is safe, effective and convenient treatment of malignant pleural effusion, and is worth clinical application.